On April 11, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), reported that preclinical data on the CTLA-4 x OX40 bispecific antibody ATOR-1015 is published in the Journal for ImmunoTherapy of Cancer (Press release, Alligator Bioscience, APR 11, 2019, View Source [SID1234538666]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The published data show that ATOR-1015 localizes to the tumor with anti-tumor effects in several experimental tumor models, including bladder, colon and pancreas cancer. Furthermore, the data demonstrate that ATOR-1015 induces a tumor-specific and long-term immunological memory and an enhanced anti-tumor response in combination with PD-1 blocking therapy.

The data support the ongoing clinical development of ATOR-1015, currently evaluated in a first-in-human Phase I study (NCT03782467). The results of this study are expected to read out in the second half of 2020.

Title: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.

Journal: Journal for ImmunoTherapy of Cancer (View Source)

Authors: Anne Månsson-Kvarnhammar et al.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CEST on April 11, 2019.

About ATOR-1015
ATOR-1015 is tumor-localizing CTLA-4 bispecific antibody with augmented depletion of regulatory T cells. It is wholly-owned by Alligator. ATOR-1015 binds to two different immune receptors: the checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40. The immune activation is increased in areas where both target molecules are expressed at high levels, notably in the tumor microenvironment, which is believed to reduce adverse immune reactions.